Published in Haematologica on June 16, 2009
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell (2010) 3.49
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Transcriptional regulation and its misregulation in disease. Cell (2013) 2.92
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell (2015) 2.20
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood (2014) 1.89
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood (2010) 1.87
The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis. PLoS Biol (2010) 1.81
Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A (2011) 1.56
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun (2012) 1.49
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood (2010) 1.30
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol (2010) 1.24
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood (2014) 1.23
Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest (2014) 1.20
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
Initiation of MLL-rearranged AML is dependent on C/EBPα. J Exp Med (2013) 1.13
New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC). J Neuroimmune Pharmacol (2011) 1.06
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia (2012) 1.05
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res (2013) 1.04
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene (2012) 0.95
Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol (2015) 0.95
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics (2016) 0.95
HTLV-1 HBZ protein deregulates interactions between cellular factors and the KIX domain of p300/CBP. J Mol Biol (2011) 0.94
Viral-host interactions that control HIV-1 transcriptional elongation. Chem Rev (2013) 0.93
Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! Haematologica (2009) 0.91
High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. J Med Chem (2014) 0.89
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
The genetic and epigenetic journey of embryonic stem cells into mature neural cells. Front Genet (2012) 0.87
Psip1/Ledgf p75 restrains Hox gene expression by recruiting both trithorax and polycomb group proteins. Nucleic Acids Res (2014) 0.87
MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep (2013) 0.86
Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis. Cytoskeleton (Hoboken) (2014) 0.85
The interaction of MYC with the trithorax protein ASH2L promotes gene transcription by regulating H3K27 modification. Nucleic Acids Res (2014) 0.85
In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One (2010) 0.85
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol (2015) 0.84
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun (2015) 0.84
Human ALKBH4 interacts with proteins associated with transcription. PLoS One (2012) 0.83
The histone methyltransferase KMT2B is required for RNA polymerase II association and protection from DNA methylation at the MagohB CpG island promoter. Mol Cell Biol (2013) 0.83
Widely expressed Af17 is likely not required for embryogenesis, hematopoiesis, and animal survival. Genesis (2010) 0.83
Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci (2014) 0.83
Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 0.82
Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification. Cancer Genet (2012) 0.82
[Thyroid-like follicular carcinoma of the kidney: a separate tumor entity?]. Pathologe (2014) 0.81
Mapping of MN1 sequences necessary for myeloid transformation. PLoS One (2013) 0.81
MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood (2015) 0.81
AF10 plays a key role in the survival of uncommitted hematopoietic cells. PLoS One (2012) 0.81
Thyroid-like follicular carcinoma of the kidney: A report of two cases and literature review. Oncol Lett (2014) 0.81
Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Leukemia (2014) 0.81
p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol (2013) 0.80
Estimating developmental states of tumors and normal tissues using a linear time-ordered model. BMC Bioinformatics (2011) 0.80
RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol Cancer (2014) 0.80
TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia. Leukemia (2014) 0.79
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach. ACS Med Chem Lett (2016) 0.79
Acute lymphoblastic leukemia and developmental biology: a crucial interrelationship. Cell Cycle (2011) 0.79
Rare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to Therapy. Oncol Rev (2015) 0.79
Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia (2015) 0.79
Challenges and opportunities in targeting the menin-MLL interaction. Future Med Chem (2014) 0.79
Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation. Bone Marrow Transplant (2014) 0.78
Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. J Mol Diagn (2010) 0.78
Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers. Genes (Basel) (2015) 0.78
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
Ectopic expression of homeobox gene NKX2-1 in diffuse large B-cell lymphoma is mediated by aberrant chromatin modifications. PLoS One (2013) 0.77
Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Elife (2015) 0.77
The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression. J Exp Clin Cancer Res (2016) 0.77
The elongation complex components BRD4 and MLLT3/AF9 are transcriptional coactivators of nuclear retinoid receptors. PLoS One (2013) 0.77
A novel disrupter of telomere silencing 1-like (DOT1L) interaction is required for signal transducer and activator of transcription 1 (STAT1)-activated gene expression. J Biol Chem (2011) 0.76
Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. Cell Rep (2016) 0.76
PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Res (2016) 0.76
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett (2016) 0.76
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res (2016) 0.76
Trithorax and polycomb cooperation in MLL fusion acute leukemia. Haematologica (2013) 0.76
Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology. Assay Drug Dev Technol (2013) 0.76
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus. Mol Cell Pediatr (2016) 0.75
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia (2016) 0.75
Primetime for Learning Genes. Genes (Basel) (2017) 0.75
Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. Yale J Biol Med (2016) 0.75
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Controlling the elongation phase of transcription with P-TEFb. Mol Cell (2006) 9.95
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell (1992) 6.11
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A (2005) 5.53
The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell (1992) 5.39
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc Natl Acad Sci U S A (2001) 5.19
A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med (2005) 4.88
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol (2008) 4.56
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila. Proc Natl Acad Sci U S A (1988) 4.21
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev (2007) 4.07
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
COMPASS, a histone H3 (Lysine 4) methyltransferase required for telomeric silencing of gene expression. J Biol Chem (2002) 4.05
Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J (1997) 4.03
The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev (2006) 3.85
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
An RNA polymerase II elongation factor encoded by the human ELL gene. Science (1996) 3.46
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet (1992) 3.43
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet (2006) 3.39
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell (2003) 3.35
Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A (1991) 3.25
The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol (2006) 3.03
Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J (2006) 2.89
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. Proc Natl Acad Sci U S A (1990) 2.85
Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol (2005) 2.74
11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A (1994) 2.67
Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol (2003) 2.66
Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet (2006) 2.62
MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol (2001) 2.58
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell (2003) 2.54
The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci U S A (1998) 2.52
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature (2008) 2.51
The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol (1998) 2.48
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res (2005) 2.45
The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res (2002) 2.43
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev (2008) 2.41
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell (2009) 2.32
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex. Nat Struct Mol Biol (2006) 2.29
Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell (2007) 2.23
Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev (2006) 2.20
Poised polymerases: on your mark...get set...go! Mol Cell (2008) 2.20
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol (2004) 2.10
Structural basis for molecular recognition and presentation of histone H3 by WDR5. EMBO J (2006) 2.08
Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood (1998) 2.06
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood (2006) 2.05
MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A (1997) 2.01
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol (2004) 1.94
Trithorax regulates multiple homeotic genes in the bithorax and Antennapedia complexes and exerts different tissue-specific, parasegment-specific and promoter-specific effects on each. Development (1993) 1.92
Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood (2004) 1.90
Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J (2000) 1.87
Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol (2007) 1.84
MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A (2003) 1.83
The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. Proc Natl Acad Sci U S A (2001) 1.82
Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res (2007) 1.82
Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood (2002) 1.79
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell (2003) 1.79
All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood (1997) 1.71
Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol (2007) 1.66
c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood (2006) 1.64
The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene (2005) 1.64
Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol (2000) 1.57
ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood (2002) 1.54
The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood (2009) 1.53
Lineage switch in acute leukemia. Blood (1984) 1.51
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood (2001) 1.42
The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol (2001) 1.40
A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. Oncogene (1999) 1.39
Molecular characterization of the trithorax gene, a positive regulator of homeotic gene expression in Drosophila. Mech Dev (1991) 1.36
Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res (2009) 1.35
Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J (2009) 1.32
The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia (2004) 1.30
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2004) 1.30
Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem (2005) 1.23
Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res (2001) 1.20
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood (1985) 1.19
Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood (2004) 1.18
Continuous MLL-ENL expression is necessary to establish a "Hox Code" and maintain immortalization of hematopoietic progenitor cells. Cancer Res (2005) 1.18